REVEILLER Marie

I manage a research project aimed to identify the mechanisms by which the gastric reflux contents initiate the Barrett’s esophagus disease, precursor of the adenocarcinoma. I supervise a team composed of a technician and a graduate student, under the supervision of Dr Godfrey and Dr Peters. Using microarrays, cell culture and human biopsies, we found that an altered key pathway was involved in the development of Barrett’s esophagus that could lead to new and effective prevention and treatment strategies.
I also contribute to other project aimed to identify biomarkers to predict progression from normal esophagus to Barrett’s and adenocarcinoma.

This project was managed in collaboration with ASTRAZENECA and urologists from Lyon-Sud Hospital.
Mission: Specified cell death mechanisms induced by ligand TRAIL and its receptors in normal and cancer prostate in relation to hormonal status and to optimize Casodex medical use.
Strategy:
-Identified TRAIL-receptors implicated in apoptosis in rat prostate induced by castration;
-Showed the role of these receptors in apoptosis in a prostate cancer cell line;
-Combined treatments in vitro to improve apoptosis of cancer cells;
-Developed a mouse model of prostate cancer and study Casodex® action (kinetic, dose effect).

Mission: Specified the role of an extracellular matrix protein “tenascin-X” on myocyte differentiation, and more particularly the active domains of this protein.
Strategy:
-Produced a high quantity of several recombinant proteins of tenascin-X in mammal cells and purified them using affinity chromatography.
-Tested these recombinant proteins in vitro on myocyte adhesion, proliferation and differentiation.